HIV Patients On Complex Regimens Are Top Candidates For Bixlenvo
The FDA approval of Gilead’s once-daily combination of bictegravir and lenacapavir opens a new option for the minority of patients who still take multiple HIV pills per day.
Scrip - August 27, 2026

Axendia: 63% Of Life Science Pros Expect AI Spending To Rise In 2027 Despite ‘Poor’ Data Quality
A survey of 194 life sciences and medtech professionals showed that 63% expect AI investments to rise in 2027 with the highest investment in commissioning, qualification and validation (CQV), according to Axendia. But only half of surveyed respondents rate their company’s data quality as sufficient.
Medtech Insight - August 27, 2026

Epitel, Prapela Are First To Win READI-Home Spots As FDA Eyes Home-Care Devices
The FDA has selected Epitel's wearable EEG system and Prapela's infant cardiac device as the first participants in its READI-Home Innovation Challenge, which aims to cut hospital readmissions. Up to nine devices may be selected; submissions close Sept. 30.
Medtech Insight - August 27, 2026

Another Sign Of Recovery? Biopharma Bankruptcy Numbers Shrink
BDO’s Life Sciences Resilience Report 2026 shows that the number of drug developer Chapter 7 and Chapter 11 bankruptcies fell from 16 in 2024 to six in 2025.
Scrip - August 27, 2026

ViiV’s Tivicay PD Gets FDA Nod For Underserved Pediatric HIV Population
The FDA approved the oral suspension tablet formulation of Tivicay for children from 4 weeks of age to under 6 years, a population that is very small in the US but underserved.
Scrip - August 27, 2026

Americans Want to Know When AI Touches Their Care — And Mostly They Don’t
A Pew survey of 3,488 US adults finds 72% want to be told if AI is used in their care and 46% do not know if it has already happened — a transparency gap that may matter more to public trust in healthcare AI than adoption rates alone.
Medtech Insight - August 27, 2026

AC Immune Scouts For New CEO And Pivots To In-House R&D
The Swiss biotech still has big pharma partnerships in Alzheimer's disease but is putting more focus on developing its in-house pipeline, especially in Parkinson's disease
Scrip - August 27, 2026

FDA Flags Another Safety Issue With J&J’s Abiomed Impella Controllers
The FDA has issued another early alert involving Abiomed’s Automated Impella Controllers, citing a purge cassette recognition problem. Three deaths and 37 serious injuries have been linked to the alert, which follows a series of recent safety events involving the Impella system.
Medtech Insight - August 27, 2026

Tezspire Closes Gap On Dupixent With EoE Trial Win
AstraZeneca and Amgen’s thymic stromal lymphopoietin inhibitor, which is already approved for severe asthma and chronic rhinosinusitis with nasal polyps, is heading to the regulators after hitting its primary goals in an eosinophilic esophagitis trial.
Scrip - August 27, 2026

Execs On The Move: August 17–21, 2026
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
Medtech Insight - August 27, 2026

People On The Move: Appointments At Karo Healthcare, Moberg Pharma, Lonza
A round-up of the latest moves in Europe's consumer health sector: Karo Healthcare names chief operations officer; Moberg Pharma adds two management team members; Lonza creates chief commercial officer role.
HBW Insight - August 27, 2026

Adalvo Announces Generic Brivaracetam Launch Across Europe
Adalvo has announced the day-one launch through European partners of its brivaracetam rival to Briviact.
Generics Bulletin - August 27, 2026

Celltrion Follows Samsung Bioepis Into Korean Keytruda Race
Celltrion has filed its CT-P51 Keytruda biosimilar for approval across 16 indications in South Korea, following Samsung Bioepis into regulatory review while also updating on a planned KRW300bn manufacturing investment.
Generics Bulletin - August 27, 2026

Apotex Launches Help Offset Lenalidomide Slide And Ophthalmic Pause
Despite lower lenalidomide turnover and a temporary pause in sales of ophthalmic products in the US due to plant remediation activities, Apotex is pushing ahead with fresh launches that will help offset a slide for its generics business in its financial first quarter.
Generics Bulletin - August 27, 2026

Norwich Optimistic After Appeals Court Opens Door For Xifaxan Reversal
Norwich Pharmaceuticals has convinced a US appeals court to reverse in part a district court ruling supporting the FDA's decision not to grant full approval of its Xifaxan (rifaximin) generic – and parent firm Lotus says it now expects an ANDA approval from the agency “in the near term”.
Generics Bulletin - August 27, 2026

FTF Gold Rush And How The US 180-Day Exclusivity Window Is Getting Crowded
Indian firms lead Paragraph IV filings in the US as a wave of blockbuster drugs lose exclusivity between 2026-2028, but the first-to-file race is getting fiercer with over a dozen filers seen for products like AstraZeneca's Farxiga, Merck’s Bridion and BMS/Pfizer’s Eliquis.
Scrip - August 27, 2026

Chinese Rivals To Revolution’s Rasonque Line Up In The Clinic
A total of eight pan-RAS inhibitors from Chinese firms are currently being developed in preclinical or early-stage clinical studies, with the most advanced, Genfleet's GFH276, set to read out Phase I results during ESMO in October.
Scrip - August 27, 2026

Sports AI Platform BAiO Wants To Catch What Clinicians Don’t See — Not Replace Their Judgment
Chirag Patel built BAiO around deliberate constraints — no diagnosis, no prediction, no autonomous decisions — and is frank that the category it sits in earned its skepticism long before BAiO arrived.
Medtech Insight - August 27, 2026

Cyberattack Makes Boston Scientific The Latest Medtech Target As Orders Are Disrupted
Medical device giant hit by cybersecurity incident on Aug. 25, triggering network outages, shipment disruptions and work-from-home orders for thousands of employees. The scope, data impact and financial hit remain unknown; shares fell about 4%.
Medtech Insight - August 27, 2026

What Is A TechBio, Exactly? France Is Betting The Definition Matters
The France TechBio Commission was born partly from a meeting at the Élysée Palace and a simple question from the President's office: how can we help if we don't know what you are?
In Vivo - August 27, 2026